JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (80)
2024
-
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
Biomedicine and Pharmacotherapy, Vol. 174
2023
-
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
Neuropharmacology, Vol. 237
-
Endocannabinoid-Binding Receptors as Drug Targets
Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94
-
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108
-
The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
Brain Sciences, Vol. 13, Núm. 9
2022
-
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Biomolecules, Vol. 12, Núm. 9
-
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Neuropharmacology, Vol. 205
2021
-
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease
European Journal of Pharmacology, Vol. 895
-
Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 22
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47
-
Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Brain Pathology, Vol. 31, Núm. 6
-
Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments
Frontiers in Molecular Neuroscience, Vol. 13
-
Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease
Molecules, Vol. 26, Núm. 11
-
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Molecular and Cellular Neuroscience, Vol. 110
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387
2020
-
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Neurobiology of Disease, Vol. 141
-
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
Scientific Reports, Vol. 10, Núm. 1
-
Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders
Biomolecules, Vol. 10, Núm. 2